Research shows that a protein called DGKE helps stop kidney filter cells from moving out of place, and boosting it reduced kidney damage and protein leakage in three separate mouse models of kidney disease. According to research reviewed by Gram, the finding points to DGKE as a possible future drug target, though human treatments are not yet available.
Kidney disease often starts when tiny filter cells called podocytes become damaged and move out of place. A new study reviewed by Gram Research analysis looked at how a protein called DGKE affects these cells. Researchers found that kidney biopsies from people with kidney disease had less DGKE, and that lower levels matched poorer kidney filtering. People with kidney disease also had more migrasomes, tiny sacs released by moving cells, in their urine. When scientists boosted DGKE in the filter cells of mice, the animals had less kidney damage and leaked less protein in three different disease models. The study was done in lab and animal research, so it does not yet show whether this approach would work in people. Still, it suggests DGKE could become a future target for new kidney treatments.
Key Statistics
A 2026 study published in Cell Death and Differentiation found that boosting the protein DGKE in kidney filter cells reduced kidney damage and protein leakage in three separate mouse models of kidney disease.
A 2026 study published in Cell Death and Differentiation found that people with glomerular disease had lower levels of the protein DGKE in kidney tissue, and those lower levels were linked to weaker kidney filtering.
A 2026 study published in Cell Death and Differentiation reported that people with kidney disease had higher levels of migrasomes in their urine, and these levels were negatively linked to DGKE.
The Quick Take
- What they studied: The researchers wanted to know whether a protein called DGKE helps control how kidney filter cells move, and whether it could protect those cells from damage that leads to kidney disease.
- Who participated: The study combined kidney tissue samples and urine tests from people with kidney disease with experiments in mice. The number of human participants was not stated in the summary provided, and the mouse experiments used three separate disease models.
- Key finding: People with kidney disease had less DGKE in their kidney tissue, and lower DGKE levels matched poorer kidney filtering. When DGKE was boosted in mouse filter cells, the mice had less kidney damage and less protein leaking into their urine in all three disease models.
- What it means for you: This is early laboratory and animal research, so it does not give you a treatment or a reason to change your care. It may point toward future kidney medicines, and anyone with kidney disease should keep working with their doctor on proven treatments.
The Research Details
The study started by looking at kidney tissue samples taken from patients with kidney diseases that affect the glomeruli, the tiny filters inside the kidneys. The researchers measured how much DGKE was present and compared those levels with each patient’s kidney filtering rate, a common measure of kidney health. They also measured migrasomes in urine, which act as a marker of cell movement.
Next, the team tested the idea in mice. They used three different methods to cause kidney damage, so that the results would not depend on a single type of injury. In some mice, they increased DGKE specifically in the podocytes, the filter cells, and then checked for kidney damage and protein leakage.
Finally, the researchers studied the cell signals behind the effect. They found that DGKE influences a chain of molecular messengers, including uPAR, beta3 integrin, Rac1, and Cdc42, that control how cells move and attach to surfaces.
Looking at human tissue shows whether DGKE levels are linked to real disease in people. Testing in mice then shows whether changing DGKE can cause a difference, not just whether the two are connected. Using three separate models makes it more likely that the effect is real and not a quirk of one experiment.
The study was published in Cell Death and Differentiation, a respected journal in cell biology. It combines several types of evidence, from human samples to animal experiments and cell signaling tests, which strengthens the overall picture. However, the summary does not report the number of human participants or mice, and the human evidence is based on tissue and urine links rather than a clinical trial. Results from mice do not always carry over to people.
What the Results Show
The first main finding was that kidney tissue from people with glomerular disease contained less DGKE than tissue from healthy comparisons. The amount of DGKE also tracked with estimated glomerular filtration rate, the standard measure of how well the kidneys filter blood. In simple terms, the less DGKE present, the weaker the kidney filtering tended to be.
The second main finding involved migrasomes. People with kidney disease had higher levels of these tiny sacs in their urine, which suggests their filter cells were moving more than normal. Migrasomes were negatively linked to DGKE, meaning that the more DGKE a person had, the fewer migrasomes they tended to show.
The third main finding came from the mouse experiments. When DGKE was boosted in the podocytes, the mice showed less injury to these cells and less protein leaking into their urine. This happened across three different methods of causing kidney damage, which makes the result more convincing.
The researchers also found that DGKE controls cell movement through a signaling pathway involving uPAR, beta3 integrin, and the Rac1 and Cdc42 messengers. These molecules help cells grip surfaces and decide when to move, so changing them can change how the filter cells behave.
The study suggests that cell movement is an important part of how podocytes get damaged. Measuring migrasomes in urine may become a simple way to track this process, although that idea still needs testing in larger human studies. The pathway identified in the study also offers several possible targets for future drugs, since it involves specific molecules that could be adjusted.
Earlier research has shown that podocyte damage and loss are central to many kidney diseases, and that current treatments often focus on reducing symptoms rather than repairing these cells. This study adds a specific protein and signaling pathway to that picture. It also builds on growing interest in migrasomes as a possible marker of cell movement, which is a newer area of research.
The most important limitation is that most of the proof comes from mice, and mouse biology does not perfectly match human biology. The human part of the study looked at tissue and urine markers rather than testing a treatment in patients. The summary also does not report sample sizes, so it is hard to judge how strong each comparison is. Finally, the study shows that DGKE is linked to kidney protection, but it does not yet prove that adding DGKE as a treatment would be safe or effective in people.
The Bottom Line
Based on current evidence, there are no changes to diet, supplements, or treatment that this study supports for people today. The findings give moderate confidence that DGKE plays a real role in protecting kidney filter cells in animals, and low to moderate confidence that it could become a useful treatment target in people. Anyone with kidney concerns should follow established medical advice.
People living with kidney disease, kidney doctors, and researchers developing new kidney medicines should pay close attention to this work. People without kidney problems do not need to change anything based on this study alone. Anyone with a family history of kidney disease, diabetes, or high blood pressure should talk with a doctor about routine kidney checks.
Lab and animal findings like these usually take many years to reach patients. Testing a new drug in people typically requires several phases of clinical trials over a decade or more. Any benefit for patients from this specific discovery is likely to be years away, and it is not yet known whether it will lead to a usable treatment.
Frequently Asked Questions
What is DGKE and how does it affect the kidneys?
DGKE is a protein found in kidney filter cells called podocytes. Research reviewed by Gram found that it helps control how these cells move, and lower DGKE levels were linked to weaker kidney filtering in patients.
Can DGKE treat kidney disease in people right now?
No human treatment based on DGKE exists yet. The 2026 study showed protective effects in three mouse models, so DGKE is considered a possible future drug target that would need years of clinical testing.
What are podocytes and why do they matter for kidney health?
Podocytes are tiny filter cells in the kidneys that help keep protein in the blood while letting waste pass into urine. When they are damaged or move abnormally, protein can leak into urine, which is a key sign of kidney disease.
What are migrasomes and why were they measured in urine?
Migrasomes are tiny sacs released by moving cells. In this study, people with glomerular disease had higher migrasome levels in urine, suggesting abnormal cell movement, and these levels were negatively linked to DGKE.
Want to Apply This Research?
- Log kidney-related check-ins once a week, including fluid intake, blood pressure readings, and any foamy urine or swelling you notice, and record the date of your most recent kidney test result such as eGFR or urine protein if your doctor has ordered them.
- Use the app to schedule and log routine kidney health checkups, and set reminders to drink water consistently, limit salt, and take prescribed blood pressure medicines on time. These steps support kidney health now, regardless of the findings in this study.
- Track key kidney markers from your doctor, such as eGFR and urine protein or albumin levels, every three to six months, and record trends over time in the app. Share the trend chart with your care team so they can judge whether your kidney function is stable or changing.
This article summarizes early laboratory, tissue, and animal research on the DGKE protein and kidney disease. The findings have not been tested as a treatment in people and should not be used to change medications, diet, or medical care. Anyone with kidney symptoms or concerns, such as swelling, foamy urine, or changes in urination, should consult a qualified healthcare professional.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.